Mesoblast's NeoFuse spinal therapy backed by interim trial data
This article was originally published in Clinica
Executive Summary
Interim results from a Phase II clinical trial have backed Mesoblast's stem cell therapy, NeoFuse, as a treatment for spinal injury.